Skip to main content

Alx Oncology Holdings Inc 10-Q for FY2026 Q3

Alx Oncology Holdings Inc (ALXO)

10-Q 2026-11-16 For: 2026-09-30
View Original
Added on November 16, 2026

About this 10-Q

Alx Oncology Holdings Inc filed this 10-Q on November 16, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Alx Oncology Holdings Inc said Evo-TRP achieved a 65.0% objective response rate versus 26.1% for TRP in retained HER2-positive, CD47-high gastric cancer; nine-month net loss narrowed to $57.7 million from $78.8 million. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Net loss
$21.83M
compared with a net loss of $22.14M a year earlier
Diluted EPS
-$0.15
compared with -$0.41 a year earlier